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The reaction of CoCl2$6H2O with the quinolone antimicrobial agent ﬂumequine (Hﬂmq) in the absence or
presence of the a-diimines 2,20-bipyridine (bipy), 1,10-phenanthroline (phen) or 2,20-bipyridylamine
(bipyam) resulted in the formation of four mononuclear complexes which were characterized with
physicochemical and spectroscopic techniques. The crystal structures of [Co(ﬂmq)2(bipy)]$2H2O,
[Co(ﬂmq)2(phen)]$1.6MeOH$0.4H2O and [Co(ﬂmq)2(bipyam)]$H2O were determined by X-ray
crystallography. The interaction of the complexes with calf-thymus DNA (CT DNA) was investigated by
UV spectroscopy, viscosity measurements, cyclic voltammetry and competitive studies with ethidium
bromide in order to evaluate the possible DNA-binding mode and to calculate the corresponding DNA-
binding constants. The binding of the complexes to human or bovine serum albumin was studied by
ﬂuorescence emission spectroscopy and the corresponding binding constants were determined. The
antimicrobial activity of the Co(II)–ﬂumequine and the recently reported Cu(II)–ﬂumequine complexes
was tested against four diﬀerent microorganisms (Escherichia coli, Xanthomonas campestris,
Staphylococcus aureus and Bacillus subtilis) and was found to be similar to that of free Hﬂmq. The
antiproliferative activity of previously reported complexes [Cu(ﬂmq)(phen)Cl], [Zn(ﬂmq)(phen)Cl] and
[Ni(ﬂmq)2(phen)] against human ovarian (A2780) and lung (A549) cancer cell lines is also reported in
comparison to the cobalt analogue, [Co(ﬂmq)(phen)Cl], 3, highlighting important diﬀerences among the
various complexes which may be due to diﬀerent uptake and modes of action.Introduction
Quinolones (quinolonecarboxylic acids or 4-quinolones) are
synthetic antibacterial drugs bearing a 4-oxo-1,4-
dihydroquinoline skeleton and are widely used for the treat-
ment of many infections including urinary tract, respiratory and
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hemistry 2016pneumonia and acute bronchitis.1–3 For the time being, quino-
lones are among the most clinically successful antibacterial
agents4 with the enzymes gyrases (type II topoisomerases) and
topoisomerase IV that participate in DNA replication being their
main biological targets.5–7 Microbial resistance to drugs is a big
public health threat to the world nowadays. Various studies
have been performed to explain and to solve this diﬃcult issue.
For example, quinazolinediones (diones), uoroquinolone-like
topoisomerase poisons that are unaﬀected by common
quinolone-resistance mutations, were tested to bypass uo-
roquinolone resistance.8 It is known that the most common
causes of quinolone resistance are mutations of specic amino-
acid residues in the gyrase or topoisomerase IV enzyme and
these amino-acids are proposed to serve as a critical enzyme–
quinolone interaction site. Metal ions, especially magnesium
(but also others were tested), are involved in these processes.
Serine and glutamic acid residues act by anchoring a water–
metal ion bridge that coordinates drug binding.9 Results of
various studies also suggest that the cell intake route of free
quinolone is diﬀerent from that of quinolone–metal
complexes.10 This supports the suitability of metal complexes as
candidates for further biological testing in quinolone resistant
microorganisms. Within this context, the interaction ofRSC Adv., 2016, 6, 19555–19570 | 19555
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View Article Onlinequinolones as well as their metal complexes with various types
of DNA has been studied as a means to better explain their
antibacterial activity on diverse microorganisms.11–13 Further-
more, these compounds have been tested for antibacterial
activity on diverse microorganisms,14–18 and their cytotoxicity
and potential antitumor activity19–27withmetal complexes of the
drugs being, in many cases, more active than their parent
compounds.2,28
Flumequine (Hmq) is a rst-generation quinolone and is
structurally related to ooxacin, nalidixic acid and oxolinic
acid.29,30Hmq is chiral and a racemic mixture (Fig. 1) is used as
a ligand. It is highly potent for the treatment of urinary tract
infections, since it is active against some Gram-positive and
Gram-negative microorganisms.31,32 Diverse nickel(II),33 cop-
per(II)34 and zinc(II)35,36 complexes with umequine as ligand
have been structurally characterized and recently reported.28
The most well-known and most important biological role of
cobalt is its presence in the active center of vitamin B12; as
a result, cobalt is considered to participate indirectly in the
regulation of DNA synthesis.37 Cobalt is also used as a supple-
ment to the vitamin B12 and is related to more than eight
cobalt-dependent proteins.37,38 In the last six decades, the
interest of researchers in regard to the biological activity of
cobalt compounds has been expanding.39 More specically, the
cobalt complex doxovir (or CTC-96) has shown antipsoriatic
activity and has already completed successfully phase II clinical
trials for the treatment of herpes simplex virus.40 Furthermore,
diverse cobalt compounds have shown antibacterial,41–43 anti-
fungal,44,45 antioxidant,46,47 antiproliferative48,49 and antiviral50,51
activity and others have been reported for hydrolytic cleavage
and binding of DNA.52 A thorough research of the literature in
regard to cobalt–quinolone complexes has revealed that Co(II)
complexes with the quinolones ciprooxacin,17 enoxacin,53
enrooxacin,18 oxolinic acid,43 noroxacin and saraoxacin54
have been structurally characterized.
As a continuation of our recent research involving the
interaction of cobalt(II) with quinolones,18,43 we report herein
the synthesis, characterization and biological properties of
cobalt(II) complexes with the rst-generation quinolone ume-
quine and the oxygen-donor methanol or the nitrogen-donors
2,20-bipyridine (bipy), 1,10-phenanthroline (phen) and 2,20-
bipyridylamine (bipyam) as co-ligands. The synthesized
compounds bear the formulas [Co(mq)2(MeOH)2], 1 and
[Co(mq)2(L)], (L ¼ bipy, phen or bipyam) for complexes 2–4,
respectively. The complexes were characterized by physico-
chemical and spectroscopic techniques and the crystalFig. 1 The racemic mixture of ﬂumequine (¼Hﬂmq).
19556 | RSC Adv., 2016, 6, 19555–19570structures of [Co(mq)2(bipy)]$2H2O, 2$2H2O, [Co(mq)2(-
phen)]$1.6MeOH$0.4H2O, 3$1.6MeOH$0.4H2O and
[Co(mq)2(bipyam)]$H2O, 4$H2O were determined by X-ray
crystallography. The interaction of complexes 1–4 with calf-
thymus (CT) DNA has been investigated by UV spectroscopy,
cyclic voltammetry, viscosity measurements and by determining
their ability to displace the well-known DNA-intercalator
ethidium bromide (EB) from its CT DNA–EB complex by uo-
rescence emission spectroscopy, in order to conclude the mode
and strength of binding. The aﬃnity of complexes 1–4 to bind to
bovine (BSA) and human (HSA) serum albumins, proteins
involved in their potential transportation through the blood-
stream, was investigated by uorescence emission spectros-
copy. The antimicrobial activity of the cobalt(II)–umequine
complexes 1–4 and the previously reported copper(II)–ume-
quine complexes [Cu(mq)2(H2O)2], 5, [Cu(mq)(bipy)Cl], 6,
[Cu(mq)(phen)Cl], 7, [Cu(mq)(bipyam)Cl], 8 and
[Cu(mq)2(py)2], 9 (py ¼ pyridine)34 was evaluated by deter-
mining the half-minimum inhibitory concentration (IC50) and
the minimum inhibitory concentration (MIC) against four
Gram-positive or Gram-negative microorganisms (i.e. Escher-
ichia coli NCTC 29212 (E. coli) Xanthomonas campestris ATCC
1395 (X. campestris), Staphylococcus aureus ATCC 6538 (S.
aureus) and Bacillus subtilis ATCC 6633 (B. subtilis)). Addition-
ally, the antiproliferative activity of recently reported complexes
[Cu(mq)(phen)Cl], 7,34 [Zn(mq)(phen)Cl], 10 (ref. 36) and
[Ni(mq)2(phen)], 11 (ref. 33) was examined against human
ovarian (A2780) and lung (A549) cancer cell lines.
Experimental
Materials – instrumentation – physical measurements
All chemicals (CoCl2$6H2O, umequine, phen, bipy, bipyam,
KOH, CT DNA, BSA, HSA, EB, NaCl, trisodium citrate) were
purchased from Sigma-Aldrich and all solvents were purchased
from Chemlab. All the chemicals and solvents were reagent
grade and were used as purchased without any further
purication.
DNA stock solution was prepared by dilution of CT DNA with
buﬀer (containing 15mM trisodium citrate and 150mMNaCl at
pH 7.0) followed by exhaustive stirring for three days, and was
kept at 4 C for no longer than a week. The stock solution of CT
DNA gave a ratio of UV absorbance at 260 and 280 nm (A260/A280)
of 1.86, indicating that DNA was suﬃciently free of protein
contamination.55 The DNA concentration was determined by
the UV absorbance at 260 nm aer 1 : 20 dilution using 3¼ 6600
M1 cm1.56
Infrared (IR) spectra (400–4000 cm1) were recorded on
a Nicolet FT-IR 6700 spectrometer with samples prepared as KBr
disks. UV-visible (UV-vis) spectra were recorded as nujol mulls
and in DMSO solution at concentrations in the range 105 to 5
 103 M on a Hitachi U-2001 dual beam spectrophotometer.
Room temperature magnetic measurements were carried out by
the Faraday method. C, H and N elemental analyses were per-
formed on a Perkin-Elmer 240B elemental analyzer. Molar
conductivity measurements of 1 mM DMSO solution of the
complexes were carried out with a Crison Basic 30This journal is © The Royal Society of Chemistry 2016
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View Article Onlineconductometer. Viscosity experiments were carried out using an
ALPHA L Fungilab rotational viscometer equipped with an 18
mL LCP spindle and the measurements were performed at 100
rpm. Fluorescence spectra were recorded in solution on a Hita-
chi F-7000 uorescence spectrophotometer.
Cyclic voltammetry studies were performed on an Eco
Chemie Autolab Electrochemical analyzer. Cyclic voltammetry
experiments were carried out in a 30 mL three-electrode elec-
trolytic cell. The working electrode was a platinum disk,
a separate Pt single-sheet electrode was used as the counter
electrode and a Ag/AgCl electrode saturated with KCl was used
as the reference electrode. Oxygen was removed by purging the
solutions with pure nitrogen which had been previously satu-
rated with solvent vapours. All electrochemical measurements
were performed at 25.0  0.2 C.Synthesis of the complexes
Synthesis of [Co(mq)2(MeOH)2], 1. Flumequine (0.4 mmol,
104 mg) was dissolved in methanol (10 mL) and was deproto-
nated by KOH (0.4 mmol, 22 mg) and then stirred for 30 min.
Aerwards, the solution was added drop-wise to a methanolic
solution (10 mL) of CoCl2$6H2O (0.2 mmol, 46 mg) followed by
30 min stirring. The resultant solution was le for slow evapo-
ration. A red–orange microcrystalline product of [Co(mq)2(-
MeOH)2] 1 (78 mg, yield: 60%) was collected aer one month.
Anal. calcd for C30H30CoF2N2O8 (MW ¼ 643.50) C 56.00, H 4.70,
N 4.35%; found: C 56.15, H 4.65, N 4.48%. IR (KBr disk): nmax,
cm1; n(C]O)pyridone, 1621 (vs (very strong)); nasym(CO2), 1585
(vs); nsym(CO2), 1377 (s (strong)); Dn(CO2) ¼ nasym(CO2)  nsym(-
CO2): 208 cm
1; UV-vis: as nujol mull, l/nm: 642 (sh (shoulder)),
528, 422 (sh), 392, 339 (sh), 326; in DMSO, l/nm (3/M1 cm1):
640 (sh) (10), 526 (40), 420 (70), 386 (550), 341 (4850), 329 (5100),
309 (5600). meﬀ at room temperature ¼ 3.94 BM. The complex is
soluble in DMSO (LM¼ 5 S cm2mol1, in 1mMDMSO solution)
and partially soluble in methanol, acetonitrile and DMF.
Synthesis of complexes [Co(mq)2(L)] 2–4, (L¼ bipy, phen or
bipyam). Complexes 2–4 were prepared by a similar procedure.
More specically, a methanolic solution (15 mL) containing
umequine (0.4 mmol, 104 mg) and KOH (0.4 mmol, 22 mg)
was stirred for 30 min. The solution was added slowly and
simultaneously with a methanolic solution of bipy (0.2 mmol,
31 mg) for 2, phen (0.2 mmol, 36 mg) for 3 or bipyam (0.2 mmol,
39 mg) for 4 to a methanolic solution (10 mL) of CoCl2$6H2O
(0.2 mmol, 48 mg). The resultant solution was stirred for 30 min
and le for slow evaporation.
[Co(mq)2(bipy)]$2H2O, 2$2H2O. Orange crystals of
[Co(mq)2(bipy)]$2H2O, 2$2H2O (100 mg, yield: 65%) suitable
for X-ray structure determination, were collected aer twenty
days. Anal. calcd for [Co(mq)2(bipy)]$2H2O (C38H34CoF2N4O8)
(MW¼ 771.62): C 59.15%, H 4.44, N 7.26; found C 59.28, H 4.28,
N 7.06; IR (KBr pellet): nmax/cm
1 n(C]O)pyridone: 1636 (vs);
nasym(CO2): 1587 (vs); nsym(CO2): 1373 (s); Dn(CO2) ¼ 214 cm1;
UV-vis: as nujol mull, l/nm: 638, 532, 428, 394, 342 (sh), 329; in
DMSO, l/nm (3/M1 cm1): 640 (sh) (5), 530 (35), 425 (120), 395
(600), 341 (8100), 329 (8600), 307 (7500). meﬀ at room
temperature¼ 4.17 BM. The complex is soluble in DMSO (LM¼This journal is © The Royal Society of Chemistry 20168 S cm2 mol1, in 1 mMDMSO solution) and partially soluble in
DMF.
[Co(mq)2(phen)]$1.6MeOH$0.4H2O, 3$1.6MeOH$0.4H2O.
Red–orange crystals of [Co(mq)2(phen)]$1.6MeOH$0.4H2O,
3$1.6MeOH$0.4H2O (100 mg, yield: 60%) suitable for X-ray
structure determination, were collected aer ten days. Anal.
calcd for [Co(mq)2(phen)]$1.6MeOH$0.4H2O (C41.6H37.2CoF2-
N4O8) (MW ¼ 818.08): C 61.08, H 4.58, N 6.85; found C 61.44, H
4.41, N 6.51; IR (KBr pellet): nmax/cm
1 n(C]O)pyridone 1622 (vs);
nasym(CO2): 1589 (vs); nsym(CO2): 1373 (v); Dn(CO2) ¼ 216 cm1;
UV-vis: as nujol mull, l/nm: 650 (sh), 525, 435 (sh), 392, 328; in
DMSO, l/nm (3/M1 cm1): 645 (sh) (5), 520 (20), 430 (120), 390
(700), 339 (7600), 327 (8700), 305 (9600). meﬀ at room
temperature ¼ 4.22 BM. The complex is soluble in DMF and
DMSO (LM ¼ 9 S cm2 mol1, in 1 mM DMSO solution).
[Co(mq)2(bipyam)]$H2O, 4$H2O. Orange crystals of
[Co(mq)2(bipyam)]$2H2O, 4$2H2O (105 mg, yield: 70%) suit-
able for X-ray structure determination, were collected aer two
weeks. Anal. calcd for [Co(mq)2(bipyam)]$H2O (C38H33CoF2-
N5O7) (MW ¼ 768.62): C 59.38, H 4.33, N 9.11; found C 59.10, H
4.52, N 8.97; IR (KBr pellet): nmax/cm
1 n(C]O)pyridone 1622 (vs);
nasym(CO2): 1583 (vs); nsym(CO2): 1373 (vs); Dn(CO2) ¼ 210 cm1;
UV-vis: as nujol mull, l/nm: 650 (sh), 525 (sh), 435, 390, 333; in
DMSO, l/nm (3/M1 cm1): 645 (sh) (5), 520 (65), 430 (160), 391
(550), 339 (4100), 323 (6500), 305 (7000). meﬀ at room
temperature ¼ 4.35 BM. The complex is soluble in DMF and
DMSO (LM ¼ 10 S cm2 mol1, in 1 mM DMSO solution).
Synthesis of complexes 5–11. The synthesis and character-
ization of the copper(II), nickel(II) and zinc(II) umequine
complexes studied herein for their biological properties
([Cu(mq)2(H2O)2], 5, [Cu(mq)(bipy)Cl], 6, [Cu(mq)(phen)Cl],
7, [Cu(mq)(bipyam)Cl], 8 and [Cu(mq)2(py)2], 9 (ref. 34) as
well as [Zn(mq)(phen)Cl], 10 (ref. 36) and [Ni(mq)2(phen)], 11
(ref. 33)) have been recently reported in the corresponding
references.X-ray structure determination
Single-crystal X-ray diﬀraction data were collected at room
temperature on a Nonius Kappa CCD and Agilent Technologies
SuperNova Dual diﬀractometers using Mo-Ka radiation (l ¼
0.71073A). The data were processed using DENZO57 or CrysAlis
Pro.58 The structures were solved by direct methods imple-
mented in SIR97 (ref. 59) or SHELXLS-97 (ref. 60) and rened by
a full-matrix least-squares procedure based on F2 with SHELXL-
97.60 All the non-hydrogen atoms were rened anisotropically.
Hydrogen atoms were readily located in diﬀerence Fourier maps
and were subsequently treated as riding atoms in geometrically
idealized positions with Uiso(H)¼ kUeq(C, N or O), where k¼ 1.5
for OH and methyl groups, which were permitted to rotate but
not to tilt, and 1.2 for all other H atoms unless otherwise noted.
In the crystal structure of 2, the umequine ligands have
a disorder over two positions at C12 and C14 and at C26 and C28
with a rened occupancy in ratios 0.61 : 0.39 and 0.55 : 0.45,
respectively. Hydrogen atoms attached to water oxygen atoms
O7 and O8 were rened xing the bond lengths. In the crystal
structure of 3, the umequine ligand has a disorder over twoRSC Adv., 2016, 6, 19555–19570 | 19557
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View Article Onlinepositions at C12 and C14 with a rened occupancy in ratios
0.50 : 0.50. The C10 and C11 atoms were rened using SIMU
and DELU instructions, C11 also using ISOR instruction. Crys-
tals were isolated as mixed methanol/water solvate, with
MeOH : H2O rened ratio 0.80 : 0.20. Hydrogen atoms on water
oxygen atom O5 were not found in diﬀerence Fourier maps and
were not included in the renement. In the crystal structure of
4, the water oxygen atomO7 has a disorder over two positions in
ratio 0.72 : 0.28. Hydrogen atoms on water oxygen atomO7 were
not found in diﬀerence Fourier maps and were not included in
the renement. Crystallographic data are listed in Table 1.DNA-binding studies
Study with UV spectroscopy. The interaction of complexes 1–
4with CT DNA was studied by UV spectroscopy in our attempt to
investigate the possible binding modes to CT DNA and to
calculate the binding constants to CT DNA (Kb). The UV spectra
of CT DNA were recorded for a constant DNA concentration in
the presence of each compound at diverse [compound]/[DNA]
mixing ratios (¼r). The binding constant of the complexes
with DNA, Kb (in M
1), was determined by the Wolfe–Shimer
equation (eqn (S1)†)61 and the plots [DNA]/(3A  3f) vs. [DNA]
using the UV spectra of the complex recorded for a constant
concentration in the presence of DNA for diverse r values.
Control experiments with DMSO were performed and no
changes in the spectra of CT DNA were observed.
Cyclic voltammetry studies. The interaction of complexes 1–
4 with CT DNA was also investigated by monitoring the changes
observed in the cyclic voltammogram of a 0.40 mM 1 : 2
DMSO : buﬀer solution of complex upon addition of DNA. The
buﬀer was used as the supporting electrolyte and the cyclic
voltammograms were recorded at n ¼ 100 mV s1.Table 1 Crystallographic data for complexes [Co(ﬂmq)2(bipy)]$2H2O, 2
[Co(ﬂmq)2(bipyam)]$H2O, 4$H2O
2$2H2O
Empirical formula C38H34CoF2N4O8
Mw 771.62
T, K 293(2)
Crystal system Triclinic
Space group P1
a (A) 9.2333(2)
b (A) 9.5588(3)
c (A) 20.9349(5)
a () 98.156(2)
b () 102.649(2)
g () 96.981(2)
V (A3) 1762.20(8)
Z 2
Dcalc (g cm
3) 1.454
m (mm1) 0.557
Data collected/unique/[I > 2s(I)] 14 676/7981/6268
Restraints/parameters 4/536
S 1.005
R1, wR2 [I > 2s(I)] 0.0414/0.1064
R1, wR2 (all data) 0.0590/0.1169
Largest diﬀ. peak/hole (e A3) 0.268/0.344
19558 | RSC Adv., 2016, 6, 19555–19570DNA-viscosity measurements. The viscosity of DNA ([DNA] ¼
0.1 mM) in buﬀer solution (150 mMNaCl and 15 mM trisodium
citrate at pH 7.0) was measured in the presence of increasing
amounts of the compounds (up to the value of r ¼ 0.26). All
measurements were performed at room temperature. The ob-
tained data are presented as (h/h0)
1/3 versus r, where h is the
viscosity of DNA in the presence of the compound, and h0 is the
viscosity of DNA alone in buﬀer solution.
EB-competitive studies with uorescence spectroscopy. The
competitive studies of each complex with EB were investigated
by uorescence emission spectroscopy in order to examine
whether the complex can displace EB from its DNA–EB complex.
The DNA–EB complex was prepared by pre-treating EB (20 mM)
and CT DNA (26 mM) in buﬀer solution (150 mM NaCl and 15
mM trisodium citrate at pH 7.0). The possible intercalating
eﬀect of complexes 1–4 was studied by adding a certain amount
of a solution of the complexes step-wise into a solution of the
DNA–EB complex. The inuence of the addition of each
compound to the DNA–EB complex solution was obtained by
recording the variation of uorescence emission spectra with
excitation wavelength at 540 nm. Complexes 1–4 did not show
any uorescence at room temperature in solution or in the
presence of DNA under the same experimental conditions;
therefore, the observed quenching is attributed to the
displacement of EB from its EB–DNA complex. The values of the
Stern–Volmer constant (KSV, in M
1) have been calculated
according to the linear Stern–Volmer equation (eqn (S2)†)62 and
the plots Io/I vs. [Q].Albumin binding studies
The albumin binding study was performed by tryptophan
uorescence quenching experiments using bovine (BSA, 3 mM)$2H2O, [Co(ﬂmq)2(phen)]$1.6MeOH$0.4H2O, 3$1.6MeOH$0.4H2O and
3$1.6MeOH$0.4H2O 4$H2O
C41.6H37.2CoF2N4O8 C38H33CoF2N5O7
818.08 768.62
293(2) 293(2)
Monoclinic Monoclinic
P2/c P21/n
11.4479(4) 11.5948(10)
10.0270(3) 24.2372(15)
18.5359(7) 12.5448(9)
90.00 90.00
114.920(3) 101.391(8)
90.00 90.00
1929.60(11) 3456.0(4)
2 4
1.408 1.477
0.513 0.567
18 417/4412/3356 18 382/7890/5212
13/291 0/491
1.086 1.035
0.0612/0.1766 0.0655/0.1676
0.0754/0.1887 0.1013/0.1914
0.749/0.282 0.993/0.440
This journal is © The Royal Society of Chemistry 2016
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View Article Onlineor human serum albumin (HSA, 3 mM) in buﬀer (containing 15
mM trisodium citrate and 150 mM NaCl at pH 7.0). The
quenching of the emission intensity of tryptophan residues of
BSA at 343 nm or HSA at 351 nm was monitored using
complexes 1–4 as quencher with increasing concentration. The
uorescence emission spectra were recorded from 300 to 500
nm at an excitation wavelength of 295 nm.63 The uorescence
emission spectra of complexes 1–4 in buﬀer solutions were
recorded under the same experimental conditions (i.e. excita-
tion at 295 nm) and exhibited a maximum emission at 365
nm.33,34 Therefore, quantitative studies of the serum albumin
uorescence emission spectra were performed aer their
correction by subtracting the spectra of the compounds. The
inuence of the inner-lter eﬀect on the measurements was
evaluated by eqn (S3).†64 The Stern–Volmer and Scatchard
equations (eqn (S4)–(S6)†)65 and graphs have been used in order
to study the interaction of each quencher with the serum
albumins and calculate the dynamic quenching constant KSV (in
M1), the approximate quenching constant kq (in M
1 s1), the
SA-binding constant K (in M1) and the number of binding sites
per albumin n.Determination of the antimicrobial activity
The antimicrobial activity of Hmq and its cobalt(II) and cop-
per(II) complexes was evaluated by determining their respective
IC50 and MIC values towards two Gram-() (E. coli and X. cam-
pestris) and two Gram-(+) (S. aureus and B. subtilis) bacterial
species. Cultures of thesemicrobial strains were grown on a rich
selective agar medium and stored at 4 C. The selective media
used were nutrient agar or broth for B. subtilis and S. aureus,
yeast mold agar or broth for X. campestris and Luria agar or
broth for E. coli. Cells picked from the surface of the stored
cultures were used to initiate liquid pre-cultures of the same
selective medium at an initial turbidity of roughly 1 McFarland
unit. Pre-cultures were incubated for 24 h in a rotary shaking
incubator and subsequently they were used to inoculate the test
cultures used for the determination of MIC at an initial
turbidity of 0.5 McFarland units. The test cultures consisted of
Mueller-Hinton broth (Deben Diagnostics Ltd) containing
diﬀerent concentrations of the compounds. Diﬀerent concen-
trations were achieved as follows: the compounds were freshly
dissolved in DMSO to a concentration of 1 mg mL1 and they
were diluted with DMSO, using the method of progressive
double dilution. Thus, working solutions with decreasing
concentrations of the compounds under investigation were
achieved. The working solutions were subsequently diluted to
the nal desired concentration by addition to the growth
medium at a proportion of 2 : 98. MIC values were determined
as the lowest concentrations of the tested compounds that
inhibited visible growth of each respective organism aer a 24 h
incubation.66 Bacterial growth was determined by measuring
the turbidity of appropriately diluted cultures at 600 nm with
reference to equally diluted sterile growth medium and the
inhibition achieved was calculated by comparing the turbidity
of each culture to the average of the turbidity of three non-
inhibited cultures. The IC50 values were calculated usingThis journal is © The Royal Society of Chemistry 2016a linear regression equation of the inhibitory eﬀects of at least
three concentrations equal or higher than the MIC and the
decimal logarithm of the concentration.67 All test cultures were
grown in triplicate and for the determination of MIC, growth
had to be inhibited in at least two cultures of the triplicate. The
incubation temperature at all stages was 37 C except for X.
campestris which was cultivated at 28 C.
The eﬀect on the growth of E. coli was monitored for 48 h
using a modication of previously described methods68,69 in
sterile 96-well at bottom microtitre plates closed with sterile
standard-prole lids without condensation rings. The inoculum
of the test cultures was prepared in the same manner as for the
determination of the MIC with the diﬀerence that the initial
turbidity of 0.5 McFarland units was achieved by mixing 20 mL of
the antibiotic solution with 230 mL of the appropriately inocu-
lated Mueller-Hinton broth in each microtitre well. The covered
microtitre plates were placed in a Synergy 2 Multi-Mode Reader
(BioTek, USA), incubated at 35 C for 48 h with no shaking and
the absorbance at 600 nm was measured every 20 min.
Antiproliferative assay in cancer cells
The human lung cancer (A549) and human ovarian cancer
sensitive to cisplatin (A2780) cell lines (obtained from the Euro-
pean Centre of Cell Cultures ECACC, Salisbury, UK) were cultured
in DMEM (for A549) or RPMI (for A2780) both containing
GlutaMax-I supplemented with 10% FBS and 1% penicillin/
streptomycin (all from Invitrogen), at 37 C in a humidied
atmosphere of 95% of air and 5% CO2 (Heraeus, Germany). For
evaluation of growth inhibition, cells were seeded in 96-well
plates (Costar, Integra Biosciences, Cambridge, MA) at a concen-
tration of 104 cells per well and grown for 24 h in complete
medium. Solutions of the compounds were prepared by diluting
a freshly prepared stock solution (102 M in DMSO) of the cor-
responding compound in aqueous media (RPMI or DMEM
depending on the cell lines). The percentage of DMSO in the
culture medium never exceeded 0.2%: at this concentration
DMSO has no eﬀect on the cell viability. Cisplatin (Sigma-Aldrich)
stock solutions were freshly prepared in aqueous solutions.
Aerwards, the intermediate dilutions of the compounds were
added to the wells (200 mL) to obtain a nal concentration ranging
from 0 to 200 mM, and the cells were incubated for 72 h. Following
72 h drug exposure, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was added to the cells at
a nal concentration of 0.50 mg mL1 incubated for 3–4 h, then
the culture medium was removed and the violet formazan dis-
solved in DMSO. The optical density of each well (96-well plates)
was quantied in quadruplicate at 540 nm using a multi-well
plate reader and the percentage of surviving cells was calcu-
lated from the ratio of absorbance between treated and untreated
cells. The IC50 value was calculated as the concentration reducing
the proliferation of the cells by 50% and is presented as a mean
(SE) of at least three independent experiments.
Cell uptake studies and ICP-MS analysis
For the evaluation of the cell uptake, cells were seeded in 6-well
plates and grown to approximately 70% conuency andRSC Adv., 2016, 6, 19555–19570 | 19559
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View Article Onlineincubated with compound 3 at 100 mM for 24 h. At the end of the
incubation period, cells were rinsed with 5 mL of PBS, detached
by adding 0.4 mL enzyme free cell dissociation solution (Milli-
pore) and collected by centrifugation. Cellular extracts were
prepared according to established procedures.70
All samples were analyzed for their protein content (to
establish the number of cells per sample) prior to ICP-MS
determination using a BCA assay (Sigma Aldrich). All samples
were digested in ICP-MS grade concentrated hydrochloric acid
(Sigma Aldrich) for 3 h at room temperature and lled to a total
volume of 8 mL with ultrapure water. Indium was added as an
internal standard at a concentration of 0.5 ppb. Determinations
of total metal contents were achieved on an Elan DRC II ICP-MS
instrument (Perkin Elmer). The ICP-MS instrument was tuned
daily using a solution provided by the manufacturer containing
1 ppb each of Mg, In, Ce, Ba, Pb and U. External standards were
prepared gravimetrically in an identical matrix to the samples
(with regard to internal standard and hydrochloric acid) with
single element standards obtained from CPI International
(Amsterdam, The Netherlands). The results are expressed as
mean  SE of at least three determinations.Discussion
Synthesis and characterization of complexes 1–4
The complexes were synthesized in high yield via the aerobic
reaction of umequine, deprotonated by KOH, with CoCl2-
$6H2O in the absence (for 1) or presence of the corresponding
N,N0-donor co-ligand (L ¼ bipy, phen, bipyam) for 2–4, accord-
ing to the following equations:
CoCl2$6H2O + 2Hflmq + 2KOH + 2MeOH/ [Co(flmq)2(-
MeOH)2] + 2KCl + 8H2O (1)
CoCl2$6H2O + 2Hflmq + 2KOH + L/ [Co(flmq)2(L)] + 2KCl +
8H2O (2)
The complexes were characterized by elemental analysis, IR
and UV-vis spectroscopic techniques, magnetic measurements
at room temperature and, in the case of 2–4, by X-ray
crystallography.
The composition of complex 1 is Co : mq : MeOH ¼
1 : 2 : 2, while complexes 2–4 have a 1 : 2 : 1 Co : mq : L
composition (L ¼ bipy, phen, bipyam), as is indicated from
elemental analysis. Complexes 1–4 are soluble in DMSO and are
not electrolytes; the values of the molar conductivity of 1 mM
DMSO solution of the complexes (LM ¼ 5–10 S cm2 mol1)
might suggest a slight partial ionization, but the dissociation
degree is very low (for a 1 : 1 electrolyte, the LM value should be
70 S cm2 mol1) and, thus, we may consider that the
compounds do not dissociate in DMSO solution.43
The IR spectra of the complexes were recorded in order to
conrm the deprotonation and the binding mode of ume-
quine. In the IR spectrum of free Hmq, the bands located at
3435 (broad, medium) cm1, 1718 (s (strong)) cm1 and 1270 (s)
cm1 were attributed the n(O–H), n(C]O)carboxyl and n(C–
O)carboxyl stretching vibrations of the carboxyl group (–COOH)19560 | RSC Adv., 2016, 6, 19555–19570and at 1618 (vs) cm1 attributed to n(C]O)pyridone stretching
vibration.33,34 In the IR spectra of the cobalt(II) complexes 1–4,
the n(O–H) disappeared indicating the deprotonation of the
carboxylate group upon binding to metal ion, and the n(C]
O)carboxyl and n(C–O)carboxyl shied towards the range 1583–1589
(vs) cm1 and 1373–1377 (s) cm1 and were characterized as
antisymmetric, nasym(CO2), and symmetric, nsym(CO2), stretch-
ing vibrations of the carboxylato group, respectively. The values
of parameter Dn(CO2) [¼nasym(CO2) nsym(CO2)] are in the range
208–216 cm1 and suggest themonodentate coordinationmode
of the carboxylate group of the quinolone ligand.71 Further-
more, the n(C]O)pyridone shied up to 1621–1636 cm
1 as
a result of its coordination. All these spectral features are
characteristic of coordination of the deprotonated umequine
ligands to cobalt in a chelating bidentate mode via the pyridone
oxygen and a carboxylato oxygen.33–36
The UV-vis spectra of the complexes were recorded as nujol
mulls and in DMSO solution and present similar patterns,
suggesting thus that the complexes retain their structure in
solution. In particular, three low-intensity bands due to d–
d transitions were observed in the visible spectra of the
complexes being characteristic for distorted octahedral high-
spin Co2+ complexes;37 namely, band I in the range 640–650
nm (3 ¼ 5–10 M1 cm1) assigned to 4T1g(F)/ 4T2g transition,
band II at 520–530 nm (3¼ 20–65 M1 cm1) assigned to 4T2g(F)
/ 4A2g transition and band III at 420–430 nm (3 ¼ 70–160 M1
cm1) to 4T1g(F) /
4T1g(P) transition. Furthermore, the band
located in the range 386–395 nm (3 ¼ 550–700 M1 cm1) was
assigned to charge-transfer transition as observed in previously
reported metal–quinolone complexes.18,43
The UV-vis spectra of 1–4 were also recorded in the presence
of a series of buﬀer solutions in the pH range 6–8 (150 mMNaCl
and 15 mM trisodium citrate at pH values regulated by HCl
solution) in order to examine whether the complexes are stable
in the buﬀer solution used for the biological experiments. Since
no signicant changes (i.e. shi of the lmax or new peaks) were
observed, the integrity of the complexes in the presence of the
buﬀer solution used for the biological experiments may be
suggested. When the observations derived for UV-vis spectros-
copy (similarity of the spectra in nujol, in DMSO solution and in
mixtures of DMSO/buﬀer solution) are combined with the non-
electrolytic nature of the complexes as shown by molar
conductivity measurements, we may conclude that complexes
1–4 keep their integrity in solution.18,43
The observed values of the magnetic moment at room temper-
ature for complexes 1–4 (meﬀ ¼ 3.94–4.35 BM) are higher than the
spin-only value (¼3.87 BM), show a spin–orbit coupling which is
probably due to the t52ge
2
g electron conguration and are charac-
teristic of mononuclear high-spin Co(II) complexes (S ¼ 3/2).18,37,43Structures of the complexes
Crystal structures of complexes 2–4. The crystal structures of
the mononuclear complexes 2–4 are depicted in Fig. 2 and
selected bond distances and angles are cited in Tables 2 and S1–
S3.† The structures of the complexes will be discussed together
along with their similarities and their diﬀerences. In theseThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinecomplexes, the umequine ligands are deprotonated in
a bidentate binding mode coordinated to cobalt(II) atom via the
pyridone and a carboxylate oxygen.
The Co(II) atom is six-coordinated exhibiting a distorted
octahedral geometry and four oxygen atoms from two ume-
quine ligands and two nitrogen atoms from the bidentate N,N0-
donor co-ligand (bipy, phen, bipyam) occupy the six vertices of
the octahedron. The bond distances around the Co(II) are quite
diﬀerent; the Co–Ocarb distances [¼2.023(3)–2.052(2) A] areFig. 2 Partially labelled plot of the molecular structure of complex (A)
[Co(ﬂmq)2(bipy)], 2 (B) [Co(ﬂmq)2(phen)], 3 and (C) [Co(ﬂmq)2(bipyam)],
4. Hydrogen atoms and disorder atoms are omitted for clarity.
This journal is © The Royal Society of Chemistry 2016slightly shorter than Co–Opyr [¼2.073(2)–2.136(2) A] while the
Co–N [¼2.110(3)–2.152(2) A] distances are the longest ones.
In the structures of complexes 2 and 3, the two carboxylato
oxygen atoms are cis to each other [Ocarb–Co–Ocarb ¼ 98.45(7)
and 99.71(14), respectively] and the two pyridone oxygen atoms
[Opyr–Co–Opyr ¼ 174.66(5) and 179.11(13), respectively] are in
a trans arrangement. On the other hand, in the crystal structure
of complex 4, the arrangement of the umequine oxygen atoms
around Co(II) is diﬀerent with the pyridone oxygens [Opyr–Co–
Opyr ¼ 83.27(10)] being in a cis arrangement and the carbox-
ylato oxygen [Ocarb–Co–Ocarb ¼ 173.55(10)] lying trans to each
other. In the reported quinolone complexes of the formula
[M(Q)2(N,N0-donor)], all three diﬀerent arrangement modes of
quinolone coordinated oxygens around the metal ion have been
observed:28 (i) the carboxylato oxygens lying at cis positions and
pyridone oxygens at trans positions as in complexes 2 and 3 as
well as in [Zn(mq)2(bipy)],35 [Zn(mq)2(phen)],36 [Ni(mq)2(-
phen)]33 and [Co(erx)2(bipyam)],18 (ii) the pyridone oxygens at cis
positions and the carboxylato oxygens at trans positions as in
complex 4 and [Ni(mq)2(bipy)]33 and (iii) the carboxylato and
the pyridone oxygens at cis positions as in a series of Ni(II)–
quinolone complexes.28
The N,N0-donor ligand is almost planar with the cobalt atom
and the N–Co–N angles [¼76.13(6)–86.63(12)] are within the
range of reported values for complexes containing chelating
polycyclic a-diimines.46,72,73
In the crystal structure of 2$2H2O, the solvate water mole-
cules enable the formation of a 1D hydrogen-bonded chain
(Table S4 and Fig. S1†). The structure is further stabilized by
p/p [3.7699(19) A, 4.0082(13) A and 4.1354(16) A] (Fig. S1†)
and weak CH/p, CF/p and CH/O interactions. In the crystal
structure of 3$1.6MeOH$0.4H2O, a solvate methanol molecule
is hydrogen-bonded to the complex 3 (Table S4†) and the
structure is stabilized by p/p interactions [3.688(3) A]
(Fig. S2†) as well as by weak CH/p and CF/p interactions.
While in 2$2H2O and 3$1.6MeOH$0.4H2O the bipy and phen
ligands, respectively, are not involved in any signicant p/p
interactions and mq ligands only to some extent, in 4$H2O all
aromatic rings participate in this kind of interaction. The
intramolecular p/p interactions have a role in the stabiliza-
tion of the (ii) arrangement mode of molecular structure of 4
[3.818(2) A, 3.895(2) A, 4.147(2) A and 4.326(2) A]. Additionally,
a stack is formed through the intermolecular p/p interactions
between mq ligands of adjacent molecules [3.824(2) A]. p/p
interactions between bipyam ligands of adjacent molecules
[4.123(3) A] are enhancing the hydrogen-bonded chain formed
via N–H/O hydrogen bonds involving the bipyam NH-group
and the carboxylic oxygen atom of the mq ligand due to the
presence of water molecules (Table S4 and Fig. S3†). The
structure is further stabilized also by weak CF/p interactions.
Proposed structure for complex 1. Based on the experimental
data (IR and UV-vis spectroscopy, molar conductivity and
magnetic measurements) and aer a comparison to the litera-
ture, we may propose a structure for complex 1. Complex 1 is
expected to have a similar structure to that of [Co(cp)2(H2O)2]
(Hcp ¼ ciprooxacin).17 On the basis of IR spectra, the complex
is mononuclear with the deprotonated umequine ligandsRSC Adv., 2016, 6, 19555–19570 | 19561
Table 2 Selected bond distances and angles for complexes 2–4
Bond
[Co(mq)2(bipy)] [Co(mq)2(phen)] [Co(mq)2(bipyam)]
Distance (A) Distance (A) Distance (A)
Co–Ocarb 2.0302(14), 2.0326(16) 2.028(2) 2.023(3), 2.052(2)
Co–Opyr 2.0852(14), 2.0890(13) 2.073(2) 2.097(2), 2.136(2)
Co–N 2.1256(15), 2.1300(18) 2.152(2) 2.110(3), 2.112(3)
C–Ocarb,bound 1.253(2), 1.265(3) 1.254(3) 1.260(5), 1.266(4)
C–Ocarb,unbound 1.232(2), 1.247(3) 1.244(4) 1.236(5), 1.237(4)
C–Opyr 1.259(2), 1.260(2) 1.260(4) 1.266(4), 1.261(4)
Bond angle Angle () Angle () Angle ()
Ocarb,1–Co–Ocarb,2 98.45(7) 99.71(14) 173.55(10)
Ocarb,1–Co–Opyr,1 86.52(6), 86.93(5) 86.63(9) 86.61(10), 85.56(10)
Ocarb,1–Co–Opyr,2 92.15(7), 88.15(6) 92.79(9) 88.47(11), 90.27(10)
Ocarb–Co–N 93.52(7), 166.17(7),
93.55(6), 163.85(7)
92.11(9), 166.43(9) 89.11(12), 92.14(11),
93.67(12), 94.02(12)
Opyr–Co–Opyr 174.66(5) 179.11(13) 83.27(10)
Opyr–Co–N 83.04(6), 85.78(6),
99.33(7), 99.46(6)
94.55(9), 86.15(9) 93.27(11), 96.79(11),
175.83(11), 179.37(12)
N–Co–N 76.13(6) 77.04(13) 86.63(12)
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View Article Onlinebeing in a bidentate binding mode coordinated to cobalt ion via
the pyridone and a carboxylato oxygen. According to the
magnetic data, the complex is mononuclear with an octahedral
geometry around the Co(II) ion. The similarity of UV-vis spectra
between the complexes suggests a distorted octahedral envi-
ronment. The octahedron is formed by four oxygen atoms of the
two umequine ligands and two oxygen atoms from the meth-
anol ligands being in a trans arrangement.Interaction of the complexes with CT DNA
Quinolones are compounds that can act as antibacterial agents
because they are involved in the inhibition of DNA-replication
since their targets are the bacterial topoisomerases DNA-
gyrase (topoisomerase II) and topoisomerase IV.1–3 Therefore,
the investigation of the interaction of quinolones and their
complexes with DNA is of great interest as a rst step of
potential activity. In general, the binding of metal complexes to
double-stranded DNA occurs via a covalent or noncovalent
mode; in the noncovalent mode, the intercalation of the
complex in-between the DNA nucleobases via p/ p stacking,
the groove-binding along the grooves of the DNA helix via van
der Waals interaction or hydrogen-bonding or hydrophobic
bonding and the electrostatic interactions due to Coulomb
forces between metal complexes and the phosphate groups of
DNA are included.74
A technique that may provide useful preliminary informa-
tion concerning the interaction mode and the binding strength
of the compounds with DNA is the UV spectroscopic titration.
Initially, the UV spectra of a CT DNA solution (C ¼ 1.2 to 1.6 
104 M) were recorded in the presence of complexes 1–4 at
increasing amounts (for diﬀerent [complex]/[DNA] mixing ratios
(¼r)). The slight decrease of the intensity at lmax ¼ 258 nm
observed in the UV spectra of a CT DNA solution (1.57  104
M) in the presence of increasing amounts of complex 2, as19562 | RSC Adv., 2016, 6, 19555–19570shown representatively in Fig. 3(A), indicates that the interac-
tion of CT DNA with the complex results in the formation of
a new complex with double-helical CT DNA.75,76 Quite similar
behaviour of CT DNA is observed in the presence of the other
complexes.
As a next step, the UV spectra of a DMSO solution of
complexes 1–4 (2.5 to 5 105 M) were recorded in the presence
of CT DNA at diverse r values; any interaction between the
complex and CT DNA may perturb the intra-ligand transition
bands of the complexes during the titrations.77 In the UV spectra
of complex 2 (5  105 M), the intraligand bands at 329 nm
(band I) and at 338 nm (band II) present a slight hyper-
chromism and slight hypochromism, respectively, upon addi-
tion of increasing amounts of CT DNA (up to r0 ¼ [DNA]/
[complex] ¼ 0.8), (Fig. 3(B) for (r0 ¼ 0–0.8)) followed by the
appearance of an isosbestic point at 331 nm. Quite similar
behaviour is observed for complexes 1, 3 and 4 upon the addi-
tion of CT (Table 3). In general, the observed hypochromism
could be attributed to a p/ p* stacking interaction between
the aromatic chromophore (from umequinato and/or the N-
donor ligands) of the complex and DNA base pairs consistent
with the intercalative binding mode.78 The existing results
suggest that the complexes can bind to CT DNA, although the
exact mode of DNA-binding cannot be concluded only by UV
spectroscopic titration studies; nevertheless, more experiments
are necessary in order to further clarify the binding mode.78
The values of the DNA-binding constant (Kb) of complexes 1–
4 (Table 3) were calculated from the plots [DNA]/(3A  3f) versus
[DNA] (Fig. S4†) and the Wolfe–Shimer equation (eqn (S1)†).61
The Kb constants are relatively high and of the same magnitude
to that of free Hmq. The Kb constants indicate a strong
binding of the complexes to CT DNA, with complex 4 bearing
the highest Kb constant (¼7.88(0.12)  105 M1) among the
compounds, and are higher than that of the classicalThis journal is © The Royal Society of Chemistry 2016
Fig. 3 (A) UV spectra of CT DNA (1.57  104 M) in buﬀer solution (150 mM NaCl and 15 mM trisodium citrate at pH 7.0) in the absence or
presence of [Co(ﬂmq)2(bipy)], 2. The arrow shows the changes upon increasing amounts of the complex (up to r ¼ 0–0.6). (B) UV spectra of
DMSO solution (5  105 M) of [Co(ﬂmq)2(bipy)], 2 in the presence of increasing amounts of CT DNA. The arrows show the changes upon
increasing amounts of CT DNA (r0 ¼ 0–0.8).
Table 3 UV-band (l in nm) (percentage of the observed hyper-/hypo-
chromism (DA/A0, %), blue-/red-shift of the lmax (Dl, nm)) of Hﬂmq
and complexes 1–4 in the presence of CT DNA. DNA-binding
constants (Kb)
Compound Band (DA/A0
a, Dlb) Kb (M
1)
Hmq33 326 (15, +2), 342 (+5, +2) 3.53 (0.45)  105
[Co(mq)2(MeOH)2], 1 329 (+1, +2), 340 (4, +1) 5.76 (0.16)  105
[Co(mq)2(bipy)], 2 329 (+4, 3), 338 (5, 0) 4.73 (0.11)  105
[Co(mq)2(phen)], 3 327 (+4, 0), 339 (6, 0) 1.41 (0.22)  105
[Co(mq)2(bipyam)], 4 322 (+6, +2), 340 (3, 0) 7.88 (0.12)  105
a “+” denotes hyperchromism, “” denotes hypochromism. b “+”
denotes red-shi, “” denotes blue-shi.
Table 4 Cathodic and anodic potentials (in mV) for the redox couple
Co(II)/Co(I) of the complexes 1–4 in DMSO/buﬀer solution in the
absence or presence of CT DNA
Complex Epc(f)
a Epc(b)
b DEpc
c Epa(f)
a Epa(b)
b DEpa
c
[Co(mq)2(MeOH)2], 1 706 696 +10 563 553 +10
[Co(mq)2(bipy)], 2 711 704 +7 557 563 6
[Co(mq)2(phen)], 3 713 705 +8 526 532 6
[Co(mq)2(bipyam)], 4 717 703 +14 530 530 0
a Epc/a in DMSO/buﬀer in the absence of CT DNA (Epc/a(f)).
b Epc/a in
DMSO/buﬀer in the presence of CT DNA (Epc/a(b)).
c DEpc/a ¼ Epc/a(b) 
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View Article Onlineintercalator EB (¼1.23(0.07)  105 M1) as calculated in our
lab.79 The Kb constants of the complexes are among the highest
constants of the metal–quinolone complexes reported.28
Electrochemical techniques may be used in complement
when studying the interaction of complexes with DNA and
useful information concerning the binding mode of the
reduced and oxidized form of the complex with DNA may arise.
Cyclic voltammetry is among the most common electro-
chemical techniques used for such studies since the shi of the
electrochemical potentials of the complex in the presence of
DNA may reveal their interaction mode; a positive shi occurs
upon intercalation and a negative shi is a result of an elec-
trostatic interaction between the complex and DNA.80,81
In particular, the cyclic voltammograms of complexes 1–4
(0.4 mM) in 1/2 DMSO/buﬀer solution were recorded in the
presence of CT DNA (representatively shown for 2 in Fig. S5†),
the cathodic (Epc) and anodic (Epa) potentials of the quasi-
reversible redox couple Co(II)/Co(I) were found and their shis
were calculated (Table 4). The cathodic and the anodic poten-
tials exhibited in the presence of CT DNA mainly a positive shi
(DEp ¼ (6)–(+14) mV) suggesting intercalation as the most
likely interaction mode between the complexes and CT DNA
bases;81 a conclusion which sheds light on the ndings of theThis journal is © The Royal Society of Chemistry 2016spectroscopic studies and is in accordance with the viscosity
experiments.
The study of the DNA viscosity in the presence of
a compound may provide signicant information in regard to
the DNA-binding mode, since the relative DNA-viscosity (h/h0) is
rather sensitive to changes of the relative DNA-length (L/L0) as
they are related by the equation L/L0¼ (h/h0)1/3.18,43 The viscosity
of a CT DNA solution (0.1 mM) wasmonitored in the presence of
increasing amounts of complexes 1–4 (up to the value of r ¼
0.27, Fig. 4). The relative viscosity showed an increase upon
addition of the complexes; such behaviour can be attributed to
a DNA-length increase arising from the insertion of the
complexes in-between the DNA bases, as a result of an inter-
calative binding mode between DNA and each complex.
Therefore, intercalation may be considered the most likely
interaction mode between DNA and complexes 1–4, as
concluded by the cyclic voltammetry studies, too.
Ethidium bromide (EB ¼ 3,8-diamino-5-ethyl-6-phenyl-
phenanthridinium bromide) intercalates to CT DNA via its
planar phenanthridine ring in-between adjacent base pairs of
the DNA double helix; thus, enhanced uorescence emission
due to the formation of the EB–DNA compound appears. EB is
a typical indicator of intercalation; the quenching of the DNA–
EB uorescence emission may occur with the co-existence ofEpc/a(f).
RSC Adv., 2016, 6, 19555–19570 | 19563
Fig. 4 Relative viscosity (h/h0)
1/3 of CT DNA ([DNA]¼ 0.1 mM) in buﬀer
solution (150 mM NaCl and 15 mM trisodium citrate at pH 7.0) in the
presence of complexes 1–4 at increasing amounts (r ¼ [complex]/
[DNA]).
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View Article Onlinea compound acting as a DNA-intercalator equally or more
strongly than EB.82 Complexes 1–4 did not exhibit any signi-
cant uorescence emission at room temperature in solution or
in the presence of CT DNA, when excited at 540 nm, and their
addition to an EB-solution did not induce any quenching of the
free EB uorescence or the appearance of new peaks in the
uorescence emission spectra. Within this context, the changes
observed in the uorescence emission spectra of the EB–DNA
solution in the presence of 1–4 were used to study the
complexes’ EB-displacing ability from the EB–DNA complex.
The uorescence emission spectra (lexcit ¼ 540 nm) of pre-
treated EB–CT DNA ([EB] ¼ 20 mM, [DNA] ¼ 26 mM) exhibited
a band of signicant intensity at lem,max ¼ 592 nm as a result of
EB-intercalating into DNA base pairs. This band presented an
intense quenching upon addition of the complexes at
increasing amounts up to an r value ¼ 0.22 (Fig. 5(A) repre-
sentatively for complex 3). The addition of complexes 1–4 into
the EB–DNA solution resulted in a rather signicant quenching
(Fig. 5(B)) of the band at 592 nm (the nal uorescence is up to
26–36% of the initial EB–DNA uorescence intensity in the
presence of the complexes, Table 5); thus, the complexes may
displace EB from the EB–DNA compound and subsequently can
intercalate to CT DNA.28
The Stern–Volmer plots of EB–DNA uorescence quenching
induced by complexes 1–4 (Fig. S6†) illustrate the good agree-
ment (R ¼ 0.99) of the quenching of EB–DNA with the linear
Stern–Volmer equation (eqn (S2)†), proving, thus, that the
replacement of EB from EB–DNA by each compound results in
a decrease in the uorescence intensity.33–36 The KSV constants
(Table 5) are relatively high showing the tight bind of the
complexes to DNA; complex 4 exhibits the highest KSV constant
(¼6.24(0.27)  105 M1) among the complexes. The KSV
constants of complexes 1–4 are similar with those reported for
a series of metal complexes with umequine and other quino-
lones as ligands.2819564 | RSC Adv., 2016, 6, 19555–19570Interaction of complexes 1–4 with serum albumin
Serum albumin (SA) is responsible for the transport of ions and
drugs through the bloodstream to cells and tissues and they are
the most abundant proteins in plasma.63 The investigation of
the interaction of biologically active compounds (such as
complexes 1–4) with SA is important, since diﬀerentiated bio-
logical properties of the compound or novel transport pathways
towards their targets in the body may arise.83 Within this
context, the interaction of complexes 1–4 with human serum
albumin (HSA) and bovine serum albumin (BSA) was studied;
BSA is homologous to HSA and is the most studied SA. The
solutions of the SA exhibit an intense uorescence emission
when excited at 295 nm, with lem,max¼ 351 nm for HSA and 343
nm for BSA due to the existence of tryptophans; a tryptophan at
position 214 in HSA and two tryptophans located at position 134
and 212 for BSA.63 The umequine compounds 1–4 exhibited an
emission band with lem,max at 365 nm under the same experi-
mental conditions, i.e. excitation at 295 nm;33–36 thus, the SA
uorescence spectra were corrected before the experimental
data processing. The inner-lter eﬀect was also taken into
consideration and was calculated with eqn (S3);† it was not
found to be signicant and only slightly aﬀected the
measurements.64
The uorescence emission spectra of HSA and BSA exhibited
in the presence of complexes 1–4 a moderate (for HSA) to
signicant (for BSA) quenching of the uorescence (quenching
of the initial SA uorescence up to 61% and 75% in the
presence of complex 2 for HSA and BSA, respectively, Fig. 6). The
observed quenching in the uorescence emission spectra of the
SAs may be due to possible changes in the tryptophan envi-
ronment of SA which are induced by changes in albumin
secondary structure as a result of the binding of each complex to
SA.84
The quenching constants (kq) for the interaction of
complexes 1–4 with the albumins were calculated from the
corresponding Stern–Volmer plots (Fig. S7 and S8†) by the
Stern–Volmer quenching equation (eqn (S4)†) and their values
are given in Tables 6 and S5.† The determined values of kq
suggest signicant SA quenching ability and they are signi-
cantly higher than 1012 M1 s1 suggesting thus the existence of
a static quenching mechanism.62 The kq constants of the
complexes are of the same magnitude to the those of free
Hmq, with 2 and 4 exhibiting the highest kq for BSA (kq(BSA),2¼
1.67(0.03)  1013 M1 s1 and kq(BSA),4 ¼ 1.59(0.09)  1013
M1 s1) and 2 for HSA (kq(hSA),2 ¼ 9.00(0.31)  1012 M1 s1).
The values of the kq are within the range found for a series of
metal-complexes bearing umequine33–36 and other quinolones
as ligands.28
The binding constants (K) of the complexes to both the
albumins were determined from the corresponding Scatchard
plots (Fig. S9 and S10†) using the Scatchard equation (eqn (S6)†)
and are given in Tables 6 and S5.† The K constants of all
complexes 1–4 are relatively high and are of the same magni-
tude to those calculated for a series of metal complexes with
umequine33–36 and other quinolones as ligands.28 The
complexes exhibit for BSA higher aﬃnity than free Hmq withThis journal is © The Royal Society of Chemistry 2016
Fig. 5 (A) Fluorescence emission spectra (lexcit ¼ 540 nm) for EB–DNA ([EB] ¼ 20 mM, [DNA] ¼ 26 mM) in buﬀer solution in the absence and
presence of increasing amounts of complex 3 (up to the r value¼ 0.21). The arrow shows the changes of intensity upon increasing amounts of 3.
(B) Plot of EB relative ﬂuorescence emission intensity at lem¼ 592 nm (%) vs. r (r¼ [complex]/[DNA]) (150mMNaCl and 15mM trisodium citrate at
pH¼ 7.0) in the presence of complexes 1–4 (up to 25.7% of the initial EB–DNA ﬂuorescence emission intensity for 1, 33.3% for 2, 31.0% for 3 and
36.0% for 4).
Table 5 Percentage of EB–DNA ﬂuorescence emission quenching
(DI/Io, %) and Stern–Volmer constants (KSV) for Hﬂmq and complexes
1–4
Compound DI/Io (%) KSV (M
1)
Hmq33 55.0 1.19(0.06)  106
[Co(mq)2(MeOH)2], 1 74.3 1.27(0.24)  105
[Co(mq)2(bipy)], 2 66.7 1.73(0.75)  105
[Co(mq)2(phen)], 3 69.0 1.61(0.49)  105
[Co(mq)2(bipyam)], 4 64.0 6.24(0.27)  105
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View Article Onlinecomplexes 1 and 2 having the highest K constants (K(BSA),1 ¼
1.57(0.11)  105 M1 and K(BSA),2 ¼ 1.43(0.07)  105 M1),
while the aﬃnity of the complexes for HSA is lower than free
Hmq with complex 1 bearing the highest K constant among
the complexes (K(HSA),4 ¼ 5.04(0.26)  105 M1).Fig. 6 (A) Plot of % relative ﬂuorescence intensity at lem¼ 351 nm (%) vs. r
ﬂuorescence for 1, 39.0% for 2, 64.5% for 3 and 67.1% for 4) in buﬀer solu
relative ﬂuorescence intensity at lem¼ 343 nm (%) vs. r (r¼ [complex]/[BS
25.3% for 2, 33.5% for 3 and 25.0% for 4) in buﬀer solution (150 mM NaC
This journal is © The Royal Society of Chemistry 2016In general, the K constants of complexes 1–4 are in the range
8.18 103 to 5.04 105 M1 and are relatively high showing the
ability of the compounds to bind to albumins and get trans-
ferred by them towards their targets cells or tissues. A
comparison of the K values to the association constant of avidin
with diverse ligands (K z 1015 M1, such interactions are
considered as the strongest known non-covalent interaction)85
may reveal the ability of the compounds to get released from the
albumins probably upon arrival at their targets.84Biological activity of the complexes
Antimicrobial activity of cobalt(II) and copper(II) umequine
complexes. The antimicrobial activity of Hmq and its cobalt(II)
and copper(II) complexes was evaluated by monitoring the
growth of two Gram-negative (E. coli and X. campestris) and two
Gram-positive (B. subtilis and S. aureus) bacterial strains in the
presence of concentrations of the compounds ranging from 0 to
64 mg mL1; the obtained half-minimum inhibitory(r¼ [complex]/[HSA]) for complexes 1–4 (up to 48.5% of the initial HSA
tion (150 mM NaCl and 15 mM trisodium citrate at pH 7.0). (B) Plot of %
A]) for complexes 1–4 (up to 48.1% of the initial BSA ﬂuorescence for 1,
l and 15 mM trisodium citrate at pH 7.0).
RSC Adv., 2016, 6, 19555–19570 | 19565
Table 6 The BSA and HSA quenching (kq) and binding constants (K) for Hﬂmq and complexes 1–4
Compound kq(BSA) (M
1 s1) K(BSA) (M
1) kq(HSA) (M
1 s1) K(HSA) (M
1)
Hmq33 8.26(0.36)  1012 6.67  104 1.00(0.17)  1013 2.37  106
[Co(mq)2(MeOH)2], 1 5.22(0.32)  1012 1.57(0.11)  105 3.64(0.25)  1012 5.04(0.26)  105
[Co(mq)2(bipy)], 2 1.67(0.03)  1013 1.43(0.07)  105 9.00(0.31)  1012 2.90(0.27)  104
[Co(mq)2(phen)], 3 1.13(0.03)  1013 7.92(0.12)  104 3.17(0.14)  1012 8.18(0.35)  103
[Co(mq)2(bipyam)], 4 1.59(0.09)  1013 9.75(0.32)  104 2.65(0.11)  1012 6.03(0.33)  104
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View Article Onlineconcentration (IC50) and the minimum inhibitory concentra-
tion (MIC) values are presented in Table 7.
Flumequine and its cobalt(II) and copper(II) complexes
present inhibitory action against all the microorganisms tested,
especially against E. coli and B. subtilis, with MIC and IC50
values in the range 1–8 mg mL1 (2.44–10.79 mM) and 0.56–3.00
mg mL1 (1.13–5.82 mM), respectively. It is clear that the
complexes are similarly or slightly more active than free Hmq
against the microorganisms tested (Table 7). Based on the
concentrations expressed in molarity units, we may conclude
that the antimicrobial activity of the complexes is up to three
times higher than the activity of free Hmq. The compounds
are active against E. coli and B. subtilis (MIC ¼ 2–4 mg mL1
(2.44–10.79 mM)), while they do not seem to be very active
against the most resistant S. aureus strain (MIC ¼ 16–64 mg
mL1 (21.56–106.3 mM)).
There is no noteworthy diﬀerentiation on the activity
observed for the Co(II)–mq complexes 1–4, the Cu(II)–mq
complexes 5–9 and their corresponding Zn(II)–mq complexes
recently reported.36 Therefore, we may conclude that for such
low MIC values, the nature of the metal does not play a signi-
cant role in the antimicrobial activity and the observed activity
of the complexes may be mainly attributed to the presence of
the quinolone ligands. Complexes 1–4 are less active than the
corresponding Co(II)–enrooxacinato complexes recently re-
ported,18 since enrooxacin is a second-generation quinolone,
and its compounds may be more active than those of a rst-
generation quinolone such as umequine.
Among the ve factors responsible for the antimicrobial
activity of a complex (chelate eﬀect of ligands, nature of ligands,
nuclearity, total charge, existence and nature of counterions),86Table 7 Antimicrobial activities of Hﬂmq and its cobalt(II) 1–4 and copp
(MIC) and half-minimum inhibitory concentration (IC50) in mg mL
1 and
E. coli X. campestris
MIC IC50 MIC IC
Hmq 1(3.82) 0.56(2.14) 8(30.53) 2.8
[Co(mq)2(MeOH)2], 1 4(6.22) 1.92(2.98) 16(24.88) 6.6
[Co(mq)2(bipy)], 2 2(2.59) 0.87(1.13) 8(10.36) 4.7
[Co(mq)2(phen)], 3 2(2.44) 0.99(1.21) 8(9.78) 5.2
[Co(mq)2(bipyam)], 4 2(2.60) 0.86(1.19) 16(20.82) 4.9
[Cu(mq)2(H2O)2], 5 2(3.32) 1.22(2.03) 8(13.29) 2.8
[Cu(mq)(bipy)Cl], 6 2(3.63) 1.10(1.99) 8(14.51) 5.7
[Cu(mq)(phen)Cl], 7 2(3.18) 1.35(2.14) 8(12.71) 4.7
[Cu(mq)(bipyam)Cl], 8 2(3.65) 1.01(1.84) 8(14.59) 5.0
[Cu(mq)2(py)2], 9 4(5.39) 1.56(2.10) 8(10.79) 5.6
19566 | RSC Adv., 2016, 6, 19555–19570the nature of the ligands (the quinolone umequine and the
oxygen- or nitrogen-donors) and the chelate eﬀect of the (u-
mequinato and nitrogen-donor) ligands seem to inuence
mainly the antimicrobial activity of the complexes. There are no
evident diﬀerences that could be attributed to the nature of the
co-ligands (bipy, phen, bipyam); the other three factors (nucle-
arity, total charge and existence of counterions) do not
contribute to diversity of the antimicrobial activity since all
complexes are mononuclear and neutral.
The determination of MIC is among the generally accepted
methods used for testing the eﬀectiveness of antibiotics on
inhibiting microbial growth. On the other hand, the simulta-
neous cultivation and on-line analysis of the microorganisms in
the presence of antimicrobial agents is used to provide more
information, regarding the eﬀect of sub-MIC concentrations on
growth and the eﬀect on bacterial population growth kinetics,
than the static acquisition of single end-point determina-
tion.87–89 It was shown that umequine at MIC andMIC/2 aﬀects
the elongation of the lag phase and the reduction of growth rate,
whereas in the presence of complexes 3 and 6, a signicant
increase of the lag phase is observed but there was little or no
eﬀect on maximum growth rate (Fig. 7). The results indicate
that the bacterial growth curve is aﬀected diﬀerently by ume-
quine and by its complexes, which could be attributed to
a diﬀerent cell intake route as has been recently suggested.10 To
our knowledge, this is the rst time that this method is
employed for the determination of the antibacterial activity of
metal complexes.
In conclusion, the best inhibition is provided by the
complexes against E. coli and B. subtilis (MIC ¼ 2–4 mg mL1),
while S. aureus rather exhibits resistance to the activity of theer(II) 5–9 complexes evaluated by minimum inhibitory concentration
in mM (the values in parentheses)
B. subtilis S. aureus
50 MIC IC50 MIC IC50
2(10.76) 2(7.64) 1.47(5.61) 16(61.06) 7.5(28.63)
6(10.35) 4(6.22) 3.00(4.66) 64(99.46) 32.3(50.19)
2(6.12) 4(5.18) 2.52(3.27) 32(41.45) 16.3(21.12)
8(6.45) 4(4.89) 2.57(3.14) 64(78.23) 27.6(33.74)
7(6.47) 2(2.60) 1.51(1.96) 32(41.63) 12.9(16.78)
4(4.72) 2(3.32) 1.52(2.52) >64(>106.30) 40.2(66.78)
3(10.39) 4(7.25) 2.05(3.72) 32(58.03) 18.4(33.37)
0(7.47) 2(3.18) 1.32(2.10) 32(50.83) 16.8(26.89)
9(9.28) 4(7.29) 1.33(2.43) 32(58.35) 19.2(35.01)
8(7.65) 8(10.79) 4.32(5.82) 16(21.56) 11.8(15.90)
This journal is © The Royal Society of Chemistry 2016
Fig. 7 Growth of E. coli in the presence of (A) Hﬂmq, (B)
[Co(ﬂmq)2(phen)], 3 and (C) [Cu(ﬂmq)(bipy)Cl], 6 at three diﬀerent
concentrations (no compound, 0.5 mg mL1 of compound and 1 mg
mL1 of compound). All cultures were grown in 8% v/v DMSO.
Table 8 Antiproliferative eﬀects represented by the IC50 (in mM (SE))
for Hﬂmq, phen and complexes 3, 7, 10 and 11 against human ovarian
(A2780) and lung (A549) carcinoma cells. Cisplatin values are shown
for comparison. The values are an average of at least three indepen-
dent experiments
Compound A2780 A549
Hmq >100 >200
phen 3.7  1.5 22  4
[Co(mq)(phen)Cl], 3 >50 >50
[Cu(mq)(phen)Cl], 7 0.26  0.07 3.2  0.4
[Zn(mq)(phen)Cl], 10 2.40  0.03 3.6  0.7
[Ni(mq)2(phen)], 11 13  2 >100
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View Article Onlinecompounds. Despite the fact that the complexes are not
signicantly more active than free umequine, their IC50 and
MIC values are low and the complexes might be considered
promising for their potency as antibacterial agents.
Antiproliferative activity in cancer cells. Representative
compounds (i.e. the herewith-reported Co complex 3, as well as
the previously described complexes 7 (Cu(II)),34 10 (Zn(II))36 and
11 (Ni(II))33 with phen ligands) were evaluated for theirThis journal is © The Royal Society of Chemistry 2016antiproliferative eﬀects on human ovarian (A2780) and lung
(A549) carcinoma cells. Flumequine and 1,10-phenanthroline
were also evaluated as well as cisplatin for comparison reasons.
The antiproliferative eﬀects were assessed by measuring cell
viability following a 72 h incubation period, using a classical
MTT assay. The calculated IC50 values are summarized in Table
8.
While Hmq does not appear to be toxic in both the tested
cell lines, phen has a low IC50 in A2780 and moderate eﬀect in
A549 cells. The cobalt complex 3 is poorly cytotoxic with IC50
values above 50 mM. Interestingly, although Hmq has similar
antibacterial properties to complex 7 in most of the tested
bacterial strains, complex 7 appears to be very potent against
both cancer cell lines, with a low sub-micromolar IC50 in A2780.
Moreover, the zinc complex 10 displays similar toxicity for both
cell lines, in the same range as complex 7 in A549 cells. On the
other hand, the nickel complex 11 has only moderate toxicity on
A2780 and practically no toxicity on A549 cells. The fact that the
ligand phen also shows a high toxicity against the two cell lines
may also be accounting for the observed antiproliferative eﬀect
of the related complexes. Nonetheless, it is noteworthy that
complex 7 is ca. 10-fold more toxic than phen. On the other
hand, Ni2+ complex 11 is less toxic than phen. Remarkably, the
Zn2+ complex 10, at variance with the other complexes and both
ligands, does not display selectivity against A2780 cells and has
a similar IC50 in both tested cell lines, in the low mM range.
It is worth noting that among the four complexes studied for
their antiproliferative activity, complex 7 exhibited the highest
aﬃnity for the albumins while the DNA-binding constant of
complex 10 was two to ve times higher than that of complexes
3, 7 and 11 (Table S6†). Therefore, we may conclude that the
most cytotoxic complexes 7 and 10 presented the highest
binding aﬃnity for albumins and CT DNA, respectively.
Cell uptake studies of complex 3. In order to evaluate if the
poor cell uptake of the cobalt compound might be responsible
for its poor cytotoxic properties, cell extracts from A2780 cancer
cells were treated with 100 mM of metal compound for 24 h at 37
C and were analyzed by ICP-MS, as described in the Experi-
mental section. The metal amount corresponds to 154  43 ng
Co per 106 cells. It is worth mentioning that previously reported
studies on the cytotoxicity and uptake of CoCl2 in a lung
epithelial cell line resulted in similar IC50 values to 3, as well as
comparable metal content.70Cisplatin 1.5  0.7 11  1.1
RSC Adv., 2016, 6, 19555–19570 | 19567
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View Article OnlineConclusions
The synthesis and characterization of the cobalt(II) complexes
with the rst-generation quinolone umequine in the absence
or presence of the a-diimines 2,20-bipyridine, 1,10-phenan-
throline or 2,20-bipyridylamine was achieved. In the resultant
complexes, the deprotonated umequine ligands are biden-
tately coordinated to cobalt via the pyridone and a carboxylato
oxygen. The crystal structures of the complexes [Co(mq)2(-
bipy)]$2H2O, 2$2H2O, [Co(mq)2(phen)]$1.6MeOH$0.4H2O,
3$1.6MeOH$0.4H2O and [Co(mq)2(bipyam)]$H2O, 4$H2O were
determined by X-ray crystallography. The geometry around
Co(II) is distorted octahedral and the arrangement of the oxygen
atoms around the cobalt is similar in complexes 2 and 3 (cis
carboxylato oxygens and trans pyridone oxygens), while in
complex 4 the arrangement of the oxygens is inverted. Such
a diﬀerence in the arrangement of the coordinated oxygen
atoms around themetal was also observed in the Ni(II) and Zn(II)
complexes bearing umequinato ligands.
The interaction of the Co(II)–umequine complexes with CT
DNA was monitored by UV spectroscopy, viscosity measure-
ments, cyclic voltammetry and competitive studies with EB.
According to all techniques used, intercalation is the most likely
interaction mode of the complexes to CT DNA. Complex
[Co(mq)2(bipyam)], 4, exhibits the highest DNA-binding
constant (Kb ¼ 7.88(0.12)  105 M1), among the Co(II)–u-
mequine complexes.
The aﬃnity of complexes 1–4 with bovine or human serum
albumins was investigated by uorescence emission spectros-
copy; the complexes exhibit tight binding aﬃnity to BSA and
HSA with relatively high SA-binding constants (K¼ 8.18 103 to
5.04  105 M1). The obtained K constants are indicative of the
binding of the complexes to the albumins and their potential
for transportation and release when arriving at their targets.
The antimicrobial activity of the Co(II)–umequine and the
previously reported Cu(II)–umequine complexes was evaluated
by the MIC and the IC50 values and was comparable to that of
free Hmq against the four bacteria tested. The best inhibition
of complexes 1–9 is against E. coli; on the other hand, the
compounds are signicantly less active against the most resis-
tant microorganism S. aureus in the range of the concentrations
tested.
Finally, the new cobalt complex 3 showed poor anti-
proliferative eﬀects in vitro in cancer cells, while the copper and
zinc analogues are promising cytotoxic agents. The present
results on the interaction of the compounds with DNA or SA
support the preliminary idea that the magnitude of binding to
biomolecules such DNA or SA may be related to the cytotoxicity.
However, the number of present compounds is limited so it is
not possible to form concrete conclusions in regard to
a possible structure–activity relationship between cytotoxicity
and binding to biomolecules. Interestingly, the diversity in the
observed anticancer eﬀects may be due to diﬀerent accumula-
tion pathways and/or mode of actions for the various metal
compounds. Furthermore, it should be noted that other bio-
logical targets should be considered, such as for example19568 | RSC Adv., 2016, 6, 19555–19570damage of intracellular zinc nger proteins, as observed for
Co2+ ions in previous studies.90
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